Literature DB >> 26474081

Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospital-Based Japanese Patients.

Mieko Yamagata1, Kei Ikeda1, Kenji Tsushima1, Ken Iesato1, Mitsuhiro Abe1, Takashi Ito2, Daisuke Kashiwakuma3, Shin-Ichiro Kagami3, Itsuo Iwamoto3, Daiki Nakagomi4, Takao Sugiyama4, Yuichiro Maruyama5, Shunsuke Furuta6, David Jayne7, Takashi Uno1, Koichiro Tatsumi1, Hiroshi Nakajima1.   

Abstract

OBJECTIVE: To determine the prevalence of lung abnormalities on chest computed tomography (CT) in patients with microscopic polyangiitis (MPA), to assess the responsiveness of such abnormalities to initial treatment, and to assess associations between these abnormalities and patient and disease characteristics and mortality.
METHODS: We retrospectively identified 167 consecutive hospital-based patients with MPA in 3 hospitals in Japan. We longitudinally collected clinical information for 150 of these patients, for whom CT images obtained before treatment were available. We then determined the presence of 22 imaging components of lung abnormalities in these patients.
RESULTS: The vast majority of patients (97%) had at least 1 lung abnormality on chest CT images, including interstitial lung lesions (66%), airway lesions (66%), pleural lesions (53%), and emphysematous lesions (37%). In multivariate analyses, ground-glass opacity was associated with the Birmingham Vasculitis Activity Score, whereas 3 of 4 airway lesions were associated with myeloperoxidase-antineutrophil cytoplasmic antibodies. Latent class analysis identified a distinct group of patients with airway-predominant lung lesions. Airway lesions such as bronchiolitis and bronchovascular bundle thickening were among the components that showed improvement within 3 months of the initial treatment. An idiopathic pulmonary fibrosis pattern was the only chest CT variable that was independently associated with shorter survival.
CONCLUSION: Abnormalities in a wide range of anatomic areas, including the whole airway, can be identified in the lungs of patients with MPA before treatment. The prevalence, clustering patterns, and responsiveness to treatment of individual lung abnormalities provide groundwork for informing future studies to understand the pathophysiology of MPA.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474081     DOI: 10.1002/art.39475

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  11 in total

Review 1.  Pulmonary Involvement in Systemic Vasculitis.

Authors:  Luis Felipe Flores-Suárez; Marco A Alba; Heidegger Mateos-Toledo; Natllely Ruiz
Journal:  Curr Rheumatol Rep       Date:  2017-09       Impact factor: 4.592

Review 2.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

3.  Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias.

Authors:  Hironao Hozumi; Yoshiyuki Oyama; Hideki Yasui; Yuzo Suzuki; Masato Kono; Masato Karayama; Kazuki Furuhashi; Noriyuki Enomoto; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

4.  Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome.

Authors:  Giorgio Trivioli; Seerapani Gopaluni; Maria L Urban; Davide Gianfreda; Matthias A Cassia; Paolo G Vercelloni; Marta Calatroni; Alessandra Bettiol; Pasquale Esposito; Corrado Murtas; Federico Alberici; Federica Maritati; Lucio Manenti; Alessandra Palmisano; Giacomo Emmi; Paola Romagnani; Gabriella Moroni; Gina Gregorini; Renato A Sinico; David R W Jayne; Augusto Vaglio
Journal:  Clin Kidney J       Date:  2020-09-06

5.  Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease.

Authors:  Shogo Matsuda; Takuya Kotani; Takayasu Suzuka; Takao Kiboshi; Keisuke Fukui; Minako Wakama; Takaaki Ishida; Youhei Fujiki; Hideyuki Shiba; Koji Nagai; Kenichiro Hata; Takeshi Shoda; Yuri Ito; Shigeki Makino; Tohru Takeuchi
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

6.  Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody.

Authors:  Xin Sun; Min Peng; Ting Zhang; Zongru Li; Lan Song; Mengtao Li; Juhong Shi
Journal:  BMC Pulm Med       Date:  2021-03-16       Impact factor: 3.317

7.  Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients.

Authors:  Peining Zhou; Zhiying Li; Li Gao; Chengli Que; Haichao Li; Jing Ma; Guangfa Wang; Min Chen
Journal:  BMC Pulm Med       Date:  2022-01-12       Impact factor: 3.317

8.  Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.

Authors:  Anna Stainer; Alex Rice; Anand Devaraj; Joseph Luke Barnett; Jacqueline Donovan; Maria Kokosi; Andrew Gordon Nicholson; Tom Cairns; Athol Umfrey Wells; Elisabetta Augusta Renzoni
Journal:  BMC Pulm Med       Date:  2019-10-24       Impact factor: 3.320

9.  Microscopic Polyangiitis with Pulmonary Fibrosis: An Often-Recognized Manifestation of the Disease.

Authors:  Liam M Clifford; Jamma Li; Christopher J Renaud; Suran L Fernando
Journal:  Case Rep Rheumatol       Date:  2019-12-31

Review 10.  Pulmonary Vasculitides: A Radiological Review Emphasizing Parenchymal HRCT Features.

Authors:  Stefano Palmucci; Corrado Inì; Salvatore Cosentino; Luigi Fanzone; Stefano Di Pietro; Alessia Di Mari; Federica Galioto; Francesco Tiralongo; Giovanna Vignigni; Stefano Toscano; Gianluca Sambataro; Carlo Vancheri; Giulio Distefano; Antonio Basile
Journal:  Diagnostics (Basel)       Date:  2021-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.